Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TYMS | P04818 | 4/20 | 0.45 |
| ▸ | TK1 | P04183 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495888 | 0.92 | LMNA (0.54) | LMNASMN1; SMN2TYMSTK1TSHR | |
| SCHEMBL60737 | 0.90 | TK1 (0.52) | TYMSTK1 | |
| SCHEMBL9564565 | 0.90 | TK1 (0.52) | TYMSTK1 | |
| SCHEMBL7535867 | 0.90 | TK1 (0.52) | TYMSTK1 | |
| SCHEMBL2027058 | 0.90 | LMNA (0.50) | LMNASMN1; SMN2TYMSTK1 | |
| SCHEMBL5086844 | 0.90 | TK1 (0.47) | TYMSTK1 | |
| SCHEMBL1501551 | 0.90 | TYMS (0.44) | TYMSTK1 | |
| SCHEMBL8892073 | 0.88 | TYMS (0.43) | TYMSTK1TSHRPMP22 | |
| SCHEMBL5486401 | 0.88 | LMNA (0.46) | LMNASMN1; SMN2TYMSTK1HSP90AA1 | |
| SCHEMBL2030341 | 0.87 | TYMS (0.44) | TYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11674135-B2 | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases | X-CHEM, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10865409-B2 | Methods for tagging DNA-encoded libraries | X-CHEM, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223893-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (ES) | 2020-07-16 | — | — | US | disclosed |
| US-20200143903-A1 | METHODS FOR IDENTIFYING COMPOUNDS | MIDCAP FINANCIAL TRUST | 2020-05-07 | — | — | US | disclosed |
| EP-3427756-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | Universidad Autónoma De Barcelona (UAB) (ES) | 2019-01-16 | — | — | EP | disclosed |
| EP-2872680-B1 | DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES | X CHEM INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20150211002-A1 | DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2015-07-30 | — | — | US | disclosed |
| CN-104685115-A | DNA coding libraries with polymerase-unreadable coding oligonucleotide linkages | CHEM INC X | 2015-06-03 | — | — | CN | disclosed |
| US-20140315762-A1 | METHODS FOR TAGGING DNA-ENCODED LIBRARIES | X-CHEM, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| CN-103998658-A | Methods for tagging DNA-encoded libraries | CHEM INC X | 2014-08-20 | — | — | CN | disclosed |
| US-7262177-B2 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | CELL WORKS THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050250679-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | Cell Works Therapeutics, Inc., Delaware corporations | 2005-11-10 | — | — | US | disclosed |
| US-6906182-B2 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use | CELL WORKS THERAPEUTICS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2002043771-A9 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE | CELL WORKS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1355672-A2 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE, BIFUNCTIONAL LINKER, AND NUCLEOTIDIC MONOMERS/POLYMERS, AND RELATED COMPOSITIONS AND METHODS OF USE | Cell Works Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030032584-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use | CELL WORKS INC. (US) | 2003-02-13 | — | — | US | disclosed |
| WO-2002043771-A2 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE | CELL WORKS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032584-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use | LNPEP, B3GAT3, GALNT1 | LMNA 431/4885SMN1; SMN2 3373/4885TYMS 145/4885 |
| US-20050250679-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | LNPEP, B3GAT3, GALNT1 | LMNA 449/4885SMN1; SMN2 3310/4885TYMS 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.